AORT ARTIVION, INC.
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 784199 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.0%
TTM net income YoY-92.5%
TTM EPS YoY-56.5%
Revenue 3-yr CAGR12.4%
Net income 3-yr CAGR—
Margins
Gross margin63.3%
Operating margin2.3%
Net margin-3.7%
FCF margin-9.2%
EBITDA margin7.7%
Returns
ROE-4.0%
ROA-1.9%
ROIC (approx.)1.3%
Asset turnover0.51x
Leverage & solvency
Liabilities / assets57.2%
Debt / equity0.81x
Current ratio4.42x
Interest coverage0.41x
Cash quality & payout
Operating cash flow / net income-0.85x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue12.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $123.79M | $125.76M | $116.34M | $115.99M | $113.39M | $112.97M | $98.98M | $97.31M |
| Cost of revenue | $47.81M | $45.24M | $40.89M | $42.85M | $38.99M | $39.86M | $35.40M | $35.81M |
| Gross profit | $75.98M | $80.52M | $75.45M | $73.14M | $74.39M | $73.11M | $63.58M | $61.50M |
| R&D expense | $9.81M | $9.05M | $8.84M | $9.12M | $8.08M | $7.06M | $6.73M | $7.40M |
| SG&A expense | $63.22M | $79.83M | $60.82M | $56.84M | $57.28M | $57.66M | $54.70M | $51.43M |
| Operating income | $2.95M | -$8.36M | $5.79M | $10.68M | $12.54M | $8.38M | $2.15M | $2.67M |
| Interest expense | $8.52M | $7.25M | $5.37M | $5.53M | $6.12M | $7.27M | $7.66M | $9.74M |
| Pretax income | -$5.92M | -$11.70M | $339,000 | $6.54M | $7.06M | $3.48M | -$2.29M | -$16.60M |
| Income tax | $2.01M | $1.81M | -$1.08M | $4.11M | $554,000 | $2.14M | -$1.79M | -$119,000 |
| Net income | -$7.93M | -$13.51M | $1.42M | $2.43M | $6.50M | $1.34M | -$505,000 | -$16.48M |
| EBITDA | $10.29M | -$1.62M | $12.13M | $16.44M | $18.25M | $13.92M | $7.59M | $8.96M |
| EPS (basic) | -0.16 | -0.28 | 0.03 | — | 0.14 | 0.03 | -0.01 | — |
| EPS (diluted) | -0.16 | -0.28 | 0.03 | — | 0.13 | 0.03 | -0.01 | — |
| Weighted avg. shares (diluted) | 48.72M | 48.54M | 49.73M | — | 48.77M | 45.38M | 42.23M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $48.40M | $77.32M | $55.76M | $64.91M | $73.43M | $53.48M | $37.69M | $53.46M |
| Receivables | $94.91M | $97.93M | $91.87M | $89.76M | $88.11M | $91.44M | $87.80M | $79.46M |
| Inventory | $107.05M | $103.36M | $98.00M | $92.43M | $90.55M | $86.72M | $81.93M | $79.77M |
| Current assets | $338.81M | $371.38M | $357.52M | $358.08M | $337.50M | $318.82M | $287.30M | $290.08M |
| PP&E, net | $81.73M | $73.70M | $67.74M | $64.99M | $40.71M | $40.09M | $37.81M | $36.40M |
| Goodwill | $344.96M | $349.86M | $251.66M | $254.09M | $254.00M | $253.80M | $245.07M | $240.96M |
| Intangibles | $145.90M | $149.27M | $120.00M | $123.66M | $126.49M | $129.26M | $127.53M | $128.05M |
| Total assets | $1.04B | $1.07B | $883.16M | $884.80M | $857.66M | $838.39M | $791.16M | $789.10M |
| Current liabilities | $76.66M | $106.93M | $92.70M | $101.56M | $85.84M | $66.67M | $51.94M | $66.82M |
| Short-term debt | $0 | $0 | $0 | $0 | $0 | $73,000 | $135,000 | $195,000 |
| Long-term debt | $363.79M | $363.42M | $215.35M | $215.11M | $214.87M | $215.54M | $314.61M | $314.15M |
| Total debt | $363.79M | $363.42M | $215.35M | $215.11M | $214.87M | $215.61M | $314.75M | $314.35M |
| Total liabilities | $595.69M | $626.35M | $432.69M | $436.56M | $418.97M | $418.49M | $496.91M | $512.90M |
| Shareholders' equity | $446.40M | $445.58M | $450.47M | $448.23M | $438.69M | $419.90M | $294.25M | $276.20M |
| Net debt | $315.39M | $286.11M | $159.59M | $150.21M | $141.44M | $162.13M | $277.05M | $260.88M |
| Cash flow statement | ||||||||
| Operating cash flow | -$4.56M | -$1.27M | $1.15M | $19.56M | $22.26M | $15.01M | -$16.95M | $10.14M |
| Capital expenditure | $13.01M | $10.75M | $8.00M | $27.51M | $4.61M | $3.29M | $3.64M | $1.43M |
| Free cash flow | -$17.57M | -$12.01M | -$6.85M | -$7.95M | $17.65M | $11.72M | -$20.59M | $8.71M |
| Investing cash flow | -$13.01M | -$129.41M | -$10.50M | -$30.51M | -$4.61M | -$3.29M | -$3.64M | -$11.43M |
| Financing cash flow | -$11.28M | $152.39M | $463,000 | $2.43M | $2.32M | $2.60M | $3.94M | $174,000 |
| Depreciation & amortization | $7.34M | $6.75M | $6.34M | $5.76M | $5.72M | $5.54M | $5.45M | $6.29M |
| Stock-based compensation | $6.22M | $8.16M | $8.41M | $4.08M | $6.13M | $6.12M | $8.04M | $2.74M |
Free plan shows the latest 8 periods; Pro shows all 67 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.